As expected, there were significant differences across the diagnostic groups (MCI-AD and AD) for APOE ɛ4 status, amyloid burden and cognitive deficits (MMSE and CDR) with AD and MCI-AD groups having more APOE ɛ4 carriers and poorer performance on cognitive assessments as compared with healthy controls. This evidence concerns the gene APOE and Cognitive impairment.